Table 1 Main characteristics (means and confidence intervals or percentages) of study population by gender
RA-women (N= 1,014) | RA-men (N= 177) | P1 | Controls (N= 1,019) | P2 | ||||
|---|---|---|---|---|---|---|---|---|
Mean | 95% C.I. | Mean | 95% C.I. | Mean | 95% C.I. | |||
Age (years) | 58.7 | 58.0 to 59.4 | 60.0 | 58.4 to 61.6 | n.s. | 58.9 | 58.1 to 59.7 | n.s. |
BMI (kg/m2) | 25.0 | 24.7 to 25.3 | 25.9 | 25.4 to 26.5 | 0.01 | 25.7 | 25.5 to 26.0 | 0.002 |
Disease duration (mo.) | 138 | 131 to 145 | 138 | 119 to 157 | n.s | |||
Swollen joint count (range 0 to 28) | 3.12 | 2.81 to 3.43 | 1.98 | 1.53 to 2.43 | 0.003 | |||
DAS 28 | 3.96 | 3.90 to 4.03 | 3.55 | 3.40 to 3.70 | <0.001 | |||
HAQ score (range 0 to 3) | 1.18 | 1.13 to 1.24 | 0.87 | 0.75 to 0.99 | <0.001 | |||
ADL (range 4 to 16) | 8.41 | 3.02 to 8.22 | 7.24 | 6.85 to 7.63 | <0.001 | |||
25(OH)D (ng/ml) | 24.0 | 23.2 to 25.0 | 24.7 | 22.9 to 26.6 | n.s. | 19.3 | 18.4 to 20.2 | <0.001 |
PTH (pg/ml) | 25.0 | 24.1 to 25.9 | 24.9 | 23.2 to 26.6 | n.s. | 33.1 | 31.7 to 34.3 | <0.001 |
Pre-menopause | 35.7% | 33.2% | ns | |||||
Sun exposure time >30 minutes | 33.5% | 51.4% | 0.01 | 35% | ns | |||
Smoking | 20.8% | 20.3% | n.s. | 16.3% | <0.001 | |||
Extra-articular manifestations | 15.3% | 13.6% | n.s. | |||||
Steinbrocker Functional state >1 | 66.8% | 58.2% | n.s. | |||||
DMARDs therapy | 88.0% | 89.3% | n.s. | |||||
Anti to TNF therapy | 46.5% | 39.5% | n.s. | |||||
ACR Remission | 22.9% | 24.9% | n.s. | |||||
Good treatment response | 43.7% | 46.9% | n.s. | |||||
Osteoporosis therapy | 29.6% | 13.6% | <0.01 | |||||
Glucocorticoid therapy | 86.5% | 83.1% | n.s. | |||||
Rheumatoid Factor positive | 63.3% | 66.3% | n.s. | |||||
Anti CCP positive | 66.3% | 66.7% | n.s. | |||||